These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7865328)

  • 1. Panel discussion on vaccine development to meet U.S. and international needs. When manufacturers are unwilling to accept the risks or invest the capital: vaccine production by the Salk Institute to specifications of the U.S. Army.
    French GR
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S309. PubMed ID: 7865328
    [No Abstract]   [Full Text] [Related]  

  • 2. Panel discussion on vaccine development to meet U.S. and international needs. Perspectives on national and global HIV vaccine development: potential ways to reduce impediments for biopharmaceutical product development.
    Obijeski J
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S307-8. PubMed ID: 7865327
    [No Abstract]   [Full Text] [Related]  

  • 3. Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development: description of a successful public-private sector international collaboration.
    Bronnenkant L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S311-3. PubMed ID: 7865329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine innovation: lessons from World War II.
    Hoyt K
    J Public Health Policy; 2006; 27(1):38-57; discussion 58-60. PubMed ID: 16681187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS vaccine 'needs focused effort' as drug firms back off research.
    Butler D
    Nature; 1995 Nov; 378(6555):323-4. PubMed ID: 7477355
    [No Abstract]   [Full Text] [Related]  

  • 6. U.S. Army Military History Institute.
    King JE
    Bull Hist Dent; 1994 Jul; 42(2):87-8. PubMed ID: 7987055
    [No Abstract]   [Full Text] [Related]  

  • 7. The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902.
    Lilienfeld DE
    Perspect Biol Med; 2008; 51(2):188-98. PubMed ID: 18453724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine development: necessity as the mother of invention.
    Burnette WN
    New Biol; 1992 Apr; 4(4):269-73. PubMed ID: 1622926
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Public health and chemical-pharmaceutical companies].
    Ribeiro MA
    Hist Cienc Saude Manguinhos; 2000 Nov-2001 Feb; 7(3):607-26. PubMed ID: 16683337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advocacy group sees little progress toward an HIV vaccine.
    AIDS Policy Law; 1998 May; 13(10):1, 8-9. PubMed ID: 11365444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The U.S. vaccine supply.
    Hinman AR
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccine development moves to front burner.
    AIDS Alert; 1997 Mar; 12(3):32-3. PubMed ID: 11364191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progenics to develop HIV vaccine.
    Expert Rev Vaccines; 2004 Jun; 3(3):229-30. PubMed ID: 15176938
    [No Abstract]   [Full Text] [Related]  

  • 16. The U.S. vaccine supply.
    Schwartz HK
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the reliability of the U.S. vaccine supply: an evaluation of alternatives.
    Mowery DC; Mitchell V
    J Health Polit Policy Law; 1995; 20(4):973-1000. PubMed ID: 8770760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic obstacles to the optimal utilization of an AIDS vaccine.
    Russell PK
    J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):31-3. PubMed ID: 11364712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.
    Kitchen LW; Vaughn DW
    Vaccine; 2007 Oct; 25(41):7017-30. PubMed ID: 17728025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The birth of the greatest invention of the 20th century].
    Sevillano D; Ramos C
    Rev Esp Quimioter; 2007 Sep; 20(3):354-8. PubMed ID: 18080034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.